Tianze Jiao

ORCID: 0000-0002-2608-616X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Disease Management Strategies
  • Diabetes Treatment and Management
  • Blood Pressure and Hypertension Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Diabetes Management and Research
  • Medication Adherence and Compliance
  • Atrial Fibrillation Management and Outcomes
  • Metabolism, Diabetes, and Cancer
  • Intensive Care Unit Cognitive Disorders
  • Cardiovascular Health and Risk Factors
  • Diabetes Management and Education
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Machine Learning in Healthcare
  • Healthcare Policy and Management
  • Suicide and Self-Harm Studies
  • Statistical Methods in Clinical Trials
  • Advanced Causal Inference Techniques
  • Pharmaceutical Economics and Policy
  • Heart Failure Treatment and Management
  • Pain Management and Opioid Use
  • Asthma and respiratory diseases
  • Botulinum Toxin and Related Neurological Disorders
  • Opioid Use Disorder Treatment
  • Down syndrome and intellectual disability research
  • Sodium Intake and Health

Center for Drug Evaluation and Research
2022-2025

Florida College
2022-2025

University of Florida
2022-2025

McGill University
2021-2024

Jewish General Hospital
2021-2023

University of Utah
2012-2016

Bayer (United States)
2014

Health Economics and Outcomes Research (United Kingdom)
2014

Tiandi Science & Technology (China)
2012

Abstract Objective CDC guidelines highlight the increased suicide risk associated with abrupt discontinuations of long-term opioid therapy (LTOT). However, evidence on specific dose and duration “thresholds” LTOT for is limited. We aimed to identify trajectories before their association 6-month risk. Methods This retrospective cohort study analyzed 2016-2021 Florida Medicaid claims adult non-cancer beneficiaries discontinuation, defined as having a > 15-day gap in supply after ≥90...

10.1093/pm/pnaf044 article EN Pain Medicine 2025-04-09

Health disparities in patients with pulmonary arterial hypertension (PAH) have not been extensively reported the United States. The aim of this project was to characterize extent demographic and socioeconomic clinical outcomes within a large, diverse PAH patient population. A retrospective, population-based study electronic health record data from OneFlorida Data Trust completed. Adult seeking care one 12 Network partner healthcare systems documented diagnosis any form (PH), including PAH,...

10.1002/pul2.70041 article EN cc-by-nc Pulmonary Circulation 2025-01-01

Hypertension is a leading cause of cardiovascular diseases and morbidity, with antihypertensive drugs blood pressure management strategies having heterogeneous effects on patients. Previous authors exploited this heterogeneity to construct optimal dynamic treatment regimes for hypertension that input patient characteristics output the best drug or strategy prescribe. There is, however, lack research optimizing monitoring schedules these It unclear whether different patterns add-on could...

10.48550/arxiv.2501.08274 preprint EN arXiv (Cornell University) 2025-01-14

BACKGROUND: Previous observational studies showed left atrial appendage occlusions with the WATCHMAN device reduced 1-year mortality, which conflicted evidence generated from randomized controlled trials. We proposed to use high-dimensional propensity score (hdPS) assist in nonactive comparator selection (prevalent user of medication) and compared mortality between patients fibrillation who received (percutaneous occlusion [pLAAO]) direct oral anticoagulants 2 matched cohorts based on (1)...

10.1161/circoutcomes.124.011188 article EN Circulation Cardiovascular Quality and Outcomes 2025-03-03

Background: Antihypertensive de-escalation—reducing the number of antihypertensive medications—is sometimes warranted but may increase cardiovascular risk if not clinically appropriate. Our study investigated impact de-escalation without clinical consideration on outcomes and adverse events. Method: This is a secondary analysis Systolic Blood Pressure Intervention Trial (SPRINT), randomized open-label trial, compared intensive (target systolic blood pressure (SBP) <120mmHg) vs. standard...

10.1101/2025.04.17.25326047 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2025-04-20

<sec> <title>BACKGROUND</title> Healthcare providers must carefully monitor patients receiving long-term opioid therapy (LTOT) to minimize risks and maximize benefits. Yet, algorithms support timely intervention during patient encounters are lacking, with accurate LTOT identification in routine care being the essential first step. </sec> <title>OBJECTIVE</title> To develop validate an algorithm using electronic health record (EHR) data. <title>METHODS</title> In this cross-sectional study,...

10.2196/preprints.76999 preprint EN 2025-05-06

OBJECTIVE The Medicare Part D Senior Savings Model (SSM) took effect on 1 January 2021. In this study we estimated the number of beneficiaries who would benefit from SSM and long-term health economic consequences implementing new policy. RESEARCH DESIGN AND METHODS Data for with diabetes treated insulin were extracted 2018 Medical Expenditure Panel Survey. A validated microsimulation model impacts policy 5-year initial implementation period a 20-year extended horizon. Costs system...

10.2337/dc21-2601 article EN Diabetes Care 2022-06-14

Abstract BACKGROUND Several antihypertensive drugs are available for the primary prevention of cardiovascular disease (CVD). However, existing evidence on prescription patterns was primarily generated among patients at high CVD risk with short-term follow-up, and failed to capture impacts time patient characteristics. Our objective therefore describe longitudinal arterial hypertension in United Kingdom. METHODS This population-based cohort study used data from Clinical Practice Research...

10.1093/ajh/hpab137 article EN American Journal of Hypertension 2021-08-27

Abstract Aim The action to control cardiovascular risk in diabetes (ACCORD) trial showed a neutral average treatment effect of intensive blood glucose and pressure (BP) controls preventing major adverse events (MACE) individuals with type 2 diabetes. Yet, effects across patient subgroups have not been well understood. We aimed identify that might benefit from or BP for MACE. Materials methods As post‐hoc analysis the ACCORD trial, we included 10 251 applied causal forest tree models...

10.1111/dom.15453 article EN Diabetes Obesity and Metabolism 2024-01-31

The objective of the current study was to determine cost-utility pregabalin versus duloxetine for treating painful diabetic neuropathy (PDN) using a decision tree analysis. Literature searches identified clinical trials and real-world studies reporting efficacy, tolerability, safety, adherence, opioid usage, health care utilization, costs duloxetine. proportions patients reported in included were used probabilities model. base-case model Food Drug Administration (FDA)-approved doses (300...

10.3109/15360288.2012.671240 article EN Journal of Pain & Palliative Care Pharmacotherapy 2012-04-18

Abstract Aim To examine the associations between low cognitive performance (LCP) and diabetes‐related health indicators (including body mass index [BMI], HbA1c, systolic blood pressure [SBP], low‐density lipoprotein [LDL] self‐reported poor physical health) whether these vary across racial/ethnic subgroups. Methods We identified adults aged 60 years or older with diabetes from 2011‐2014 National Health Nutrition Examination Survey. Individuals test scores in lowest quartile were defined as...

10.1111/dom.15715 article EN Diabetes Obesity and Metabolism 2024-06-20

Statistical approaches to adaptive treatment strategies (ATS) can be used mimic the sequential decision-making inherently found in clinical practice. To illustrate use of a statistical ATS approach, we emulated target trial different blood pressure (BP) control plans for prevention cardiovascular events among individuals with hypertension at high risk, inspired by Systolic Blood Pressure Intervention Trial (SPRINT). We included 103,708 patients and "QRISK3" estimated 10-year risk disease...

10.1093/aje/kwad091 article EN American Journal of Epidemiology 2023-04-19

Abstract Aim This study compared the 5‐year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide insulin glargine in individuals with type 2 diabetes, using Building, Relating, Assessing, Validating Outcomes (BRAVO) diabetes simulation model. Research Design Methods was a SURPASS‐2 trial extrapolation, an arm added as additional comparator. The 1‐year treatment effects tirzepatide (5, 10 or 15 mg), (1 mg) on glycated haemoglobin, systolic blood...

10.1111/dom.15332 article EN Diabetes Obesity and Metabolism 2023-10-22

OBJECTIVE Patients with severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) experience high hospital readmission after being discharged. Cognitive impairment (CI) may further increase the risk, especially in those experiencing an interruption of medical care discharge. This study examined effect modification role postdischarge (PDC) on CI-associated risk among U.S. adults diabetes initially admitted for DKA SH. RESEARCH DESIGN AND METHODS We used Nationwide Readmissions Database (NRD)...

10.2337/dca23-0013 article EN Diabetes Care 2023-12-04
Coming Soon ...